C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics, Inc. director Utpal Koppikar received a grant of stock options to buy 62,000 shares of common stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.
The option award will vest and become exercisable in full on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the Board through that date. Following this grant, he holds options covering 62,000 shares directly.
C4 Therapeutics director Kenneth Carl Anderson received a grant of stock options as part of his compensation. The award covers 62,000 options to buy Common Stock at an exercise price of $4.25 per share, with no cash paid at grant.
The options vest and become exercisable in full on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, provided he continues serving on the Board through that date. The options expire on June 23, 2036 if not exercised.
C4 Therapeutics director Ronald Harold Wilfred Cooper received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.25 per share and were awarded at no cost to him.
These options vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the board through that date. After this grant, his reported holdings of this option award total 62,000 derivative securities.
C4 Therapeutics director Laura Bessen received a new stock option grant covering 62,000 shares of common stock. The option has an exercise price of $4.25 per share and expires on June 23, 2036. This is a compensation-related award, not an open‑market trade.
According to the terms, the option vests and becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as Bessen continues serving on the board through that date. After this grant, she holds 62,000 derivative securities directly.
C4 Therapeutics director Stephen Fawell was granted stock options linked to 62,000 shares of common stock. The options carry an exercise price of $4.25 per share and expire on June 23, 2036. This is a compensation-related award, not an open-market purchase.
The option grant vests and becomes exercisable in full on the earlier of June 24, 2027 or the next annual meeting of stockholders, as long as he continues serving on the Board. Following this grant, he holds options covering 62,000 shares directly.
C4 Therapeutics director Donna Roy Grogan received a new stock option grant. She was awarded options covering 62,000 shares of Common Stock at an exercise price of $4.25 per share. These options are a compensation-related award, not an open-market stock purchase or sale.
The option will vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual meeting of stockholders, provided she continues serving on the Board through that date. Following this grant, her reported holdings in this option award total 62,000 derivative securities.
C4 Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 24, 2026. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to serve until the 2029 annual meeting.
Stockholders gave a non-binding, advisory approval of named executive officer compensation and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to the 2020 Stock Option and Incentive Plan to include outstanding pre-funded warrants in the shares counted for the evergreen increase calculation.
C4 Therapeutics filed a report highlighting new clinical data and investor materials for its IKZF1/3 degrader cemsidomide in relapsed/refractory multiple myeloma. A fully enrolled Phase 1 trial of cemsidomide plus dexamethasone in 73 heavily pretreated patients showed a 53% overall response rate at the 100 µg once-daily recommended Phase 2 dose and 36% across all doses, with some responses deepening over time and minimal residual disease negativity in select patients. Median progression-free survival was 3.9 months and median duration of response was 7.9 months. Safety was characterized mainly by on‑target neutropenia, with 58% experiencing grade 3/4 neutropenia, few dose reductions and no discontinuations attributed to cemsidomide. The company is now enrolling a Phase 2 single‑arm study in fourth‑line and later multiple myeloma and a Phase 1b combination trial with the bispecific antibody elranatamab, while also outlining a broader strategy in oncology and inflammation/neuroinflammation indications.
C4 Therapeutics director Kenneth Carl Anderson exercised stock options to acquire 1,070 shares of common stock on June 1, 2026. The options were exercised at a price of $2.11 per share for cash, and no shares were sold in connection with the exercise.
Following the exercise, Anderson directly holds 69,300 shares of C4 Therapeutics common stock. Additional shares are held indirectly through several revocable and irrevocable trusts associated with Anderson and Cynthia E. Anderson, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
CCCC reported a same-day exercise-and-sale of stock options granted under its 2020 Equity Incentive Plan. The filing states 29,080 options were granted on 02/14/2025; of those, 9,087 vested and were exercised and sold pursuant to a same-day sale transaction. The filing lists brokerage details for the transaction.